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AbstractBackground: Limited data exist describing supportive care management, laboratory
abnormalities and outcomes in patients with EVD (Ebola virus disease) in West Africa. We report
data which constitute the ﬁrst description of the provision of enhanced EVD case management
protocols in a West African setting.
Methods: Demographic, clinical and laboratory data were collected by retrospective review of
clinical and laboratory records of patients with conﬁrmed EVD admitted between 5 November
2014 and 30 June 2015.
Results: A total of 44 EVD patients were admitted (median age 37 years (range 17–63), 32/44
healthcare workers), and excluding those evacuated, the case fatality rate was 49% (95% CI
33%–65%). No pregnant women were admitted. At admission 9/44 had stage 1 disease (fever and
constitutional symptoms only), 12/44 had stage 2 disease (presence of diarrhoea and/or vom-
iting) and 23/44 had stage 3 disease (presence of diarrhoea and/or vomiting with organ failure),
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with case fatality rates of 11% (95% CI 1%–58%), 27% (95% CI 6%–61%), and 70% (95% CI 47%–87%)
respectively (p = 0.009). Haemorrhage occurred in 17/41 (41%) patients. The majority (21/40) of
patients had hypokalaemia with hyperkalaemia occurring in 12/40 patients. Acute kidney injury
(AKI) occurred in 20/40 patients, with 14/20 (70%, 95% CI 46%–88%) dying, compared to 5/20
(25%, 95% CI 9%–49%) dying who did not have AKI (p = 0.01). Ebola virus (EBOV) PCR cycle
threshold value at baseline was mean 20.3 (SD 4.3) in fatal cases and 24.8 (SD 5.5) in survivors
(p = 0.007). Mean national early warning score (NEWS) at admission was 5.5 (SD 4.4) in fatal
cases and 3.0 (SD 1.9) in survivors (p = 0.02). Central venous catheters were placed in 37/41
patients and intravenous ﬂuid administered to 40/41 patients (median duration of 5 days).
Faecal management systems were inserted in 21/41 patients, urinary catheters placed in 27/41
and blood component therapy administered to 20/41 patients.
Conclusions: EVD is commonly associated life-threatening electrolyte imbalance and organ
dysfunction. We believe that the enhanced levels of protocolized care, scale and range of
medical interventions we report, offer a blueprint for the futuremanagement of EVD in resource-
limited settings.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
Introduction
The recent outbreak of Ebola virus disease (EVD) in West
Africa was unprecedented. Following the ﬁrst case in Guinea
in December 2013, 28 616 cases were reported in Guinea,
Liberia and Sierra Leone resulting in 11 310 deaths.1,2 Fragile
healthcare systems in the affected countries struggled to
cope with the scale and complexity of the outbreak, and
the World Health Organisation declared a Public Health
Emergency of International Concern on 8 August 2014,
resulting in the mobilisation of the international community
to assist in the control of the EVD outbreak in West
Africa.3
Case ﬁnding and contact tracing, combined with safe and
digniﬁed burial of corpses, are key public health measures
required to control EVD outbreaks, underpinned by social
mobilisation.4 Case management and isolation of cases in
EVD treatment centres is the fourth key pillar of outbreak
response.5,6 Whilst there were a number of investigational
therapies in development and trialled for the treatment of
EVD, none were routinely available in West Africa during the
recent outbreak. Optimising clinical outcomes therefore was
entirely dependent upon the provision of high quality sup-
portive care.
The practical difﬁculties of providing parenteral ﬂuid and
electrolyte therapy in EVD treatment centres, combinedwith
the perceived risks to healthcare workers (HCWs) of invasive
clinical procedures resulted in generally poor access to
enhanced levels of care across West Africa.7,8 During the
outbreak in Gulu, Uganda in 2000, higher levels of care were
delivered including routine use of intravenous ﬂuids with an
overall case fatality rate of 53% (224/425, 95% CI 48%–58%).
At the beginning of this outbreak some clinicians also endeav-
oured to challenge the historically poor EVD patient out-
comes with improved supportive care delivery, including the
ﬁrst ETC in Conakry that sustained at a low CFR of 30%–40%.8,9
Unfortunately, despite this progress some organisations have
failed to learn these key clinical lessons, and still question
the beneﬁt and evidence base of intravenous ﬂuid and elec-
trolyte replacement in EVD.10
As part of the international response to the EVD outbreak
inWest Africa, the UK built seven treatment centres in Sierra
Leone,11 the ﬁrst of which was commissioned on 5 November
2014 at Kerry Town, near the capital Freetown. This included
20 beds operated by the UK and Canadian Defence Medical
Services speciﬁcally for HCWs with suspected or conﬁrmed
EVD. The EVD treatment unit (EVDTU) was well resourced
with dedicated laboratory facilities and was capable of pro-
viding high quality medical and nursing care, ﬂuid and elec-
trolyte therapy, blood component transfusion, oxygen therapy
and vasopressor support.
Limited data exist describing supportive care manage-
ment, laboratory abnormalities and outcomes in patients
with EVD inWest Africa, apart fromwithin EVD clinical trials.
Patient age, baseline viral load and renal dysfunction have
been highlighted as key prognostic indicators in EVD.12,13
Combined analysis of 27 exported cases of EVD to Europe and
the United States of America (USA) also highlighted the prev-
alence of organ dysfunction in EVD and demonstrated the
feasibility and importance of critical care interventions, with
an associated low case fatality rate of 18.5% (95% CI
6.3%–38%).14 We report cohort data from Sierra Leone which
is the ﬁrst description of the provision of enhanced EVD case
management protocols in a West African setting, in a unique
treatment centre dedicated to caring for infected HCWs. It
demonstrates what can be achieved by well-resourced and
committed clinical teams and pushes the boundaries of EVD
supportive care levels in low-resource settings.
Methods
Study design
Demographic, clinical and laboratory data were collected by
retrospective review of clinical notes, nursing charts and
laboratory records of patients with conﬁrmed EVD admitted
to the military EVDTU at Kerry Town, between 5 November
2014 and 30 June 2015. Clinical features, observations and
laboratory test results were recorded each day on a
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standardised proforma. All clinical notes were electronically
scanned on patient discharge or death, prior to destruction
of the paper copies used in the EVDTU clinical area. All
clinical samples and datawere collected during routine patient
care as part of the public health response and the Sierra
Leone ethics and scientiﬁc review board conﬁrmed board
approvalwasnot required.All informationon individual patients
was anonymized and recorded on standardised forms, which
were kept securely.
Patients
Patients admitted to the military EVDTU included interna-
tional and national HCWs and other personnel engaged in the
EVD relief effort in Sierra Leone (including doctors, nurses,
community healthcare ofﬁcers, ambulance drivers and hygien-
ists). Local nationals not involved in healthcare were also
referred and admitted on a case-by-case basis, although
pregnant women and children with EVD were directed to
alternative treatment centres. Patientswere admitteddirectly
from the community, or were transferred from other treat-
ment centres once their status as a HCW was realised. Diag-
nosis of EVD was conﬁrmed on admission by EBOV real-time
reverse transcriptase polymerase chain reaction (RT-PCR)
assay of blood. Baseline data from patients subsequently
aeromedically evacuated to Europe or USA is reported, but
not included in longitudinal data reported or outcome depen-
dent regression analysis.
Blood sampling
All patients underwent EBOV RT-PCR testing on admission,
providedby theonsitePublicHealth England laboratory utilising
an existing Trombley Ebola Zaire nucleoprotein assay or the
Altona RealStar Filovirus RT-PCR Kit (Altona, Hamburg,
Germany).15 Results were reported as positive or negative,
with cycle threshold (Ct) values only being obtained retro-
spectively. The onsite military laboratory provided basic
haematology, clotting, clinical chemistry and blood culture
capabilities. On admission, and when clinically indicated
thereafter, blood samples were assayed in the onsite labo-
ratory using the Piccolo Express system (Abaxis, CA, USA),
Horiba ABXMicros ES60 analyser (Horiba, Montpellier, France)
and Hemochron Signature Elite (Accriva Diagnostics,CA, USA).
When laboratory facilitieswere not available, bedside i-STAT®
(Abbott Point of Care) testing was undertaken when indi-
cated. The Bact-Alert™ system was used for blood cultures,
and if positive a Blood Culture Identiﬁcation Detection panel
was run on the BioFire FilmArray™. A rapid diagnostic test
(RDT) was undertaken on admission to exclude malaria
(BinaxNOW®). HIV (Alere Determine HIV 1/2 Ag/Ab) and
Dengue (SD Bioline Dengue NS1 Ag Ab Combo) rapid diagnos-
tic tests were also available.
EVD treatment bundle
An EVD treatment bundle was developed to facilitate a
protocolized approach to the provision of clinical care thus
ensuring optimal utilisation of clinical contact time. Whilst
acknowledging there is little evidence of efﬁcacy of any
speciﬁc intervention in the management of EVD, the ele-
ments of the EVD treatment bundle were developed by the
clinical group encompassing interventions well established
in the management of the critically ill and incorporating
basic tenets of care provided in EVD treatment centres. The
EVD treatment bundle evolved through regular review by
clinical groups at the end of each 60-day roulement.
In the EVD treatment bundle (Annex 1), clinical disease
was deﬁned by three stages of illness (Table 1). The main
tenets of the EVD treatment bundle include parenteral ﬂuid
& electrolyte replacement therapy, stress-ulcer prophy-
laxis, empirical antibiotics and anti-helminthic medication,
analgesia and standardised approaches to the management
of coagulopathy & haemorrhage, encephalopathy and shock
(supplementary information). Venous access was routinely
achieved by placement of a central venous cannula (CVC) in
all patients with stage 2 or 3 disease. Vital signswere recorded
6 hourly with continuous monitoring of heart rate, non-
invasive blood pressure and pulse oximetry undertaken when
required (and facilitated remotely by closed circuit televi-
sion monitoring). Urethral catheterisation and placement of
faecal management systems were undertaken as clinically
indicated. All staff received education in the delivery of the
EVD treatment bundle prior to the opening of the EVDTU and
prior to each roulement of clinical staff throughout the
outbreak.16
Maximumdaily earlywarning scores (national earlywarning
score – NEWS, quick Sepsis Related Organ Failure Assess-
ment – qSOFA) were calculated retrospectively. The qSOFA
score can be calculated using basic parameters of clinical
assessment and aims to identify patients at increased risk of
death due to sepsis.17 NEWS is a scoring system (score 0–20)
Table 1 Ebola virus disease stage description.
Stage 1 Non-speciﬁc febrile illness
Stage 2 Diarrhoea and/or vomiting
without organ dysfunction
Stage 3 Diarrhoea and /or vomiting
with organ dysfunction:
-Acute kidney injury
(serum creatinine > ×2 baseline or <0.5 mL/kg /h
urine output for 12
consecutive hours: RIFLE classiﬁcation)
-Coagulopathy and/or haemorrhage
(abnormal bleeding, or APTT/ACT > ×1.5 upper
limit of normal, or
PT > ×1.5 upper limit of normal, or platelets
<100 × 10/L)
-Encephalopathy +/- seizures
(any alteration in mental status)
APTT – Activated Partial Thromboplastin Time, ACT – Activated
Clotting Time, PT – Prothrombin Time.
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based upon routine clinical observations reﬂecting the indi-
vidual’s physiological response to illness. When a patient is
admitted to amedical facility it can be used to track changes
in clinical observations thus alerting the healthcare team to
any deterioration and so triggering a timely escalation in
clinical care.18
Statistical analysis
Descriptive analyses are reported as frequencies and propor-
tions for categorical variables, means or medians as appro-
priate for continuous variables. We used Fisher’s exact test
for comparing categorical variables, and Student’s t-test
and Mann–Whitney U test for comparing continuous vari-
ables. We assessed risk factors for mortality by univariate
logistic regression and reported odds ratio of death with its
95% CI. No imputation for missing data was made due to
small sample sizes. Hypothesis tests were two-tailed (p < 0.05)
and we analysed data with SPSS (version 24).
Results
Demographics
During the study period a total of 44 cases were admitted
with conﬁrmed EVD. Three international HCWs with con-
ﬁrmed EVDwere initially managed in the EVDTU before being
evacuated to Europe or the USA for further treatment, all of
whom survived. The remaining cases were Sierra Leonean
nationals of whom 71% (29/41) were employed in health-
care. The majority of patients were male (28/44) with a
median age of 37 years (range 17–63). The mean time from
onset of illness until admission was 5.3 days (SD 3.2), with
23/44 patients admitted directly to the EVDTU (Table 1).
Excluding those whowere aeromedically evacuated, the case
fatality rate for those receiving care in the military EVDTU
was 49%.
Clinical features
At the time of admission to the EVDTU the most common
clinical features were diarrhoea and vomiting (33/44), leth-
argy (31/44), anorexia (29/44), abdominal pain (28/44) and
fever (27/44). Only 3/44 patients had signs or symptoms of
haemorrhage at admission, with 10/44 patients reporting
hiccups of which 8/10 died. Vital signs at admission were
within normal limits in the majority of patients admitted,
apart from respiratory rate (mean 24.6, SD 7.5), with mean
temperature 37.5°C (SD 1.0) at admission. Other signs and
symptoms of EVD patients admitted to the military EVDTU
are shown in Table 2. Stage 1 disease (fever & constitutional
symptoms only) was present in 9/44 patients, stage 2 disease
(presence of diarrhoea and/or vomitingwithout organ failure)
in 12/44 and stage 3 disease (presence of diarrhoea and/or
vomiting with organ failure) was present in 23/44 patients
with case fatality rates of those not evacuated of 14% (95% CI
1%–58%), 27% (95% CI 6%–61%), and 70% (95% CI 47%–87%)
respectively (p = 0.009). Cycle threshold value at baseline
was available for 42/44 participants with a mean of 22.7 (SD
5.2) overall, and 20.3 (SD 4.3) in fatal cases and 24.8 (SD 5.5)
in survivors (p = 0.007) (sTable 3).
Clinical ﬁndings during hospitalisation are summarised in
Fig. 1. Nearly all patients had diarrhoea (39/41), lasting a
median 5 days (IQR 3–6 days) and complained of abdominal
pain (38/41) lasting a median 3 days (IQR1–3 days). Lethargy
was also very common (36/41), lasting a median 3 days (IQR
1–5), with vomiting occurring in 33/41 patients and lasting a
median of 3 days (IQR 1–2). During hospitalisation fever
(>38 °C) was recorded in 33/41 patients with the median
Table 2 Demographic characteristics of EVD cases.
Total
(n = 44a)
Survived
(n = 21)
Died
(n = 20)
p-value
Gender
Male 28 (64%) 11 (53%) 16 (75%) 0.052
Female 16 (36%) 10 (47%) 4 (25%)
Age (years) Mean (SD) 37.6 (10.9) 35.0 (9.9) 41 (11.7) 0.084
Health care workers 32 (73%) 17 (83%) 12 (60%) 0.18
Non-health care workers 12 (27%) 4 (17%) 8 (40%)
Nationality
Sierra Leone nationals 41 (93%)
Other nationalities 3 (7%)
Mode of admission
Direct 23 (52%) 12 (57%) 9 (45%) 0.76
Transfer another ETC 21 (48%) 9 (43%) 11 (55%)
Time from symptom onset to admission (days)
Mean (SD)
5.3 (3.2) 4.71 (3) 6.5 (3) 0.064
Length of admission (days) n = 41a
Mean (SD)
7.4 (4.63) 10.2 (4.4) 4.4 (2.7) <0.001
Time from symptom onset until death/discharge (days) n = 41a
Median (range)
13 (5–25) 14 (8–25) 11 (5–17) 0.004
a 44 patients with conﬁrmed EVD were managed at the EVD treatment unit, with 41 admitted until discharge/death (with longitudinal
data available). 3 patients were aeromedically evacuated to the USA/Europe not included in outcome analysis. (SD – standard deviation).
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time until resolution (<38 °C) of 9 days from the onset of
symptoms. Haemorrhage occurred in 17/41 patients (and
one HCW prior to evacuation) with encephalopathy seen in
26/41 patients. The lowest oxygen saturations recorded in
fatal cases was lower than cases that survived (mean 86.6%
versus 93.9%, respectively, p = 0.003).
Laboratory results
Blood was analysed using the onsite laboratory and point of
care devices as clinically indicated and in accordance with
the EVD treatment bundle (e.g. daily in stage 2/3 disease).
During a total of 312 EVD patient admission days in the
EVDTU, themost frequentlymeasuredelectrolyteswere sodium
and potassium, analysed in 255/312 (81.7%) and 240/312
(76.9%) patient days respectively. The majority of patients
had electrolyte abnormalities at admission and during
hospitalisation (Supplementary Table S1). Hyponatraemia
(<135 mmol/L) occurred in 37/40 (93%) of patients and
hypokalaemia (<3.5 mmol/L) in 21/40 (53%) during
hospitalisation. Hyperkalaemia (>5mmol/L) occurred in 12/40
patients during admission with 3 patients recording potas-
sium levels >6 mmol/L. Hypomagnesaemia (<0.7 mmol/L)
and hypophosphataemia (<0.8mmol/L) were recognised com-
plications in 11/31 and 8/31 patients in whom magnesium
and phosphateweremeasured, typically occurring in patients
with a protracted diarrhoeal phase of illness. Hypoglycaemia
(<4mmol/L) occurred in 24/40 (60%) patients, with 9 patients
recording blood sugars ≤2.8 mmol/L, all of whomwere in the
terminal stages of illness.
Renal dysfunction frequently occurred with an elevated
creatinine (>110 umol/L) in 26/41 (63%) at admission and
32/40 (80%) during hospitalisation. Acute kidney injury (AKI)
(RIFLE criteria - creatinine> twiceestimatedbaseline) occurred
in 20/40 patients through the course of their illness, with
14/20 (70%, 95% CI 46%–88%) subsequently dying, compared
to 5/20 (25%, 95% CI 9%–49%) patients who did not suffer AKI
Table 3 Admission clinical features.
Clinical Features Total (n = 44)a Survived (n = 21) Died (n = 20) p-value
Anorexia 29/44 13/21 15/20 0.342
Abdominal pain 28/44 13/21 15/20 0.132
Back pain 9/44 5/21 4/20 1.0
Conjunctival injection 10/44 5/21 5/20 1.0
Diarrhoea & vomiting 33/44 13/21 19/20 0.006
Dyspnoea 7/44 2/21 5/20 0.217
Delirium/encephalopathy 11/44 2/21 9/20 0.012
Fever 27/44 14/21 11/20 0.539
Haemorrhage 3/44 2/21 1/20 0.583
Headache 25/44 13/21 10/20 0.543
Hiccups 10/44 2/21 8/20 0.027
Lethargy/malaise 31/44 12/21 17/20 0.096
Myalgia 25/44 11/21 12/20 0.766
Arthralgia 19/44 10/21 7/20 0.372
Nausea 23/44 9/21 13/20 0.143
Vital signs at admission
Pulse – mean (SD) 90.6 (16.9) 89.2 (19) 92 (16) 0.58
Systolic BP – mean (SD) 125 (21.3) 118 (19) 134 (21) 0.02
Temperature – median (range) 37.3 (36.1–39.6) 37.2 (36.1–39.6) 37.4 (36.3–39.2) 0.354
Respiratory rate – median (range) 22 (14–44) 23 (17–44) 22 (14–42) 0.217
Saturations – median (range) 97 (83–99) 96 (83–99) 98 (91–99) 0.02
EVD stage at admission
Stage 1 9/44 6/21 1/20
Stage 2 12/44 8/21 3/20
Stage 3 23/44 7/21 16/20 0.009
Highest EVD stage during admission
Stage 1 1/41 1/21 0/20
Stage 2 8/41 8/21 0/20 0.004
Stage 3 32/41 12/21 20/20
NEWS score at admission
Mean (SD)
4.1 (3.5) 3 (1.9) 5.5 (4.4) 0.02
qSOFA score at admission
Median (range)
1 (0–3) 1 (0–2) 1 (0–3) 0.359
Ct value at admission (n = 42)
Median
20.7 (14.3–37.2) 23.4 (16.2–37.2) 19.6 (14.3–32.1) 0.001
a 44 patients with conﬁrmed EVD were managed at the EVD treatment unit, with 41 admitted until discharge/death. 3 patients were
aeromedically evacuated to the US/Europe. (SD – standard deviation, BP – blood pressure, qSOFA – quick Sepsis Related Organ Failure
Assessment, Ct – cycle threshold).
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dying (p = 0.01). Elevated creatine kinase (>380 IU/L) devel-
oped in 33/34 (97%), with the median maximum creatine
kinase (CK) observed in patients with AKI 3200 IU/L and in
those without AKI, 3129 IU/L. Elevated alanine aminotrans-
ferase (ALT) levels (>110 IU/L) were demonstrated in all
patients in whom it was measured (35/35), with aspartate
aminotransferase (AST) enzyme levels raised in virtually all
patients (34/35) during the course of their illness. Peak AST
levels (median 1322 IU/L) were higher than peak ALT levels
(median 352 U/L). Elevated bilirubin (>21 umol/L) devel-
oped in 10/34 patients with 2/34 patients having levels
(>100 umol/L). The median C-reactive protein on admission
was 30 (n = 34), with 18/35 recording a CRP >200 (limit of
assay) during the course of their admission.
Elevated activated partial thromboplastin time (31/35,
APPT >37 s) was more common than elevations in prothrom-
bin time (18/39, PT >14 s). Overall, 18/44 (41%) patients
developed a signiﬁcant derangement in one or more assays
of global coagulation (Activated Partial Thromboplastin Time
(APTT) > 57 s, Activated Clotting Time (ACT) > 180 s or
Prothrombin Time (PT) > 23 s) during the course of their
illness. Thrombocytopenia (<150 × 109/L) was recorded in
the majority of patients (24/35), with signiﬁcant thrombo-
cytopenia (platelets < 50 × 109/L) observed in 6/35 (17%)
patients. The majority of patients with platelets < 50 × 109/L
survived (5/6) – only three of whom required platelet trans-
fusion. Leucocytosis (>15 × 109/L) occurred in 16/34 patients
and was associated with fatal outcome (p = 0.005).
Malaria RDTs were performed on all patients at admis-
sion, with results available in 37 patients, of which one was
positive. One patient was also managed empirically for
falciparummalaria as a convalescent blood transfusion tested
positive by RDT at the time of administration. Thirty-ﬁve
blood cultures were taken from 27/44 patients, with one
positive blood culture identiﬁed. Patients were on pre-
existing empirical antibiotics in 19/34 negative blood cul-
tures.Onepositive blood culture (E. coli species)was identiﬁed
from an admission sample of a 48-year-old Sierra Leonean
HCW, admitted 7 days after disease onset with severe EVD
(stage 3 disease, NEWS 10, qSOFA 2, Ct 18.3). The patient
presentedwith diarrhoea, haemorrhage and acute renal failure
and died after 3 days despite supportive therapy including
empirical ceftriaxone.
Early warning scores
At the time of admission mean NEWS score was 5.5 (SD 4.4)
in fatal cases and 3 (SD 1.9) in survivors (p = 0.02), with
mean qSOFA scores of 1 (SD 0.8) and 0.7 (0.6) respectively
(p = 0.27). The highest NEWS score recorded during the
course of admission was mean 7.2 (SD 3.7) in survivors vs.
12.8 (SD 3.3) in fatal cases (p < 0.001), with mean highest
qSOFA scores also lower in survivors (1.2, SD 0.6) compared
to fatal cases (2, SD 0.76, p < 0.001).
Clinical management
Intravenous catheters were inserted in all patients, with
central venous catheters placed in 37/41 patients, and 1/3
international HCWs prior to evacuation (Table 4). Themajor-
ity CVCs were placed within 24 hours of admission, remain-
ing in situ for amedian of 5 days. Faecal management systems
were inserted in 21/41 patients during their admission, for a
median of 3 days duration (range 1–10 days). Urinary cath-
eters were placed in 27/41 patients for a median duration of
2 days. Intravenous ﬂuid was administered to 40/41 patients
for a median duration of 5 days (range 2–17 days). The
median maximum IV ﬂuid volume administered to a patient
in 24 hours was 3.2 L (range 2-8 L). Intravenous potassium
replacement was administered to 31/41 patients, with intra-
venous magnesium and phosphate replacement adminis-
tered to18/41and6/41patients respectively. Bloodcomponent
therapy was administered to 20/41 patients, and 1 interna-
tional HCWprior to aeromedical evacuation, with fresh frozen
plasma the most frequently administered product. Conva-
lescent whole blood transfusion was administered to 4/41
0 5 10 15 20 25 30 35 40 45
Diarrhoea
Lethargy
Anorexia
Abdominal pain
Vomiting
Fever (subjective)
Myalgia
Headache 
Arthralgia
Fever (objective >38C)
Chest Pain
Dyspnoea
Encephalopathy
Hiccups
Conjunctival injection
Cough
Sore Throat
Haemorrhage
Skin Rash
Seizure
NUMBER OF CASES RECORDED 
Fig. 1. Clinical features during admission (dark grey) and hospitalisation (light grey) (total number = 41).
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patients. Empirical ceftriaxone was administered to 37/41
patients for amedian of 5 days duration (range 1–10). Oxygen
supplementation was administered to 18/41 patients, for a
median duration of 3 days (range 1–7), with 16/18 patients
having a fatal outcome. Oxygen supplementation was admin-
istered to 2 survivors for 5 and 7 days, with one recording a
lowest saturation of 77% on room air. It was provided via
oxygen concentrators and as such limited to low ﬂow rates.
No patients received vasopressors for the management of
septic shock. Univariate logistic regression analysis of factors
associated with mortality at admission is shown in Table 5.
The following laboratory variables were found to be associ-
ated with mortality at univariate analysis: AST greater than
1000 U/L (OR 6.0 95% CI 1.17–30.72); RIFLE criteria stage 2
(injury) (OR 4.8 95% CI 1.2–19.13); Granulocyte count greater
than 7.5 × 109/L (OR 5.6 95% CI 1.16–27.08); and Ct value
Table 4 Interventions during hospitalisation.
Intervention Number
Intravenous access
Peripheral catheter 39 (95%)
Duration (days), median (range) n = 39 4 (1–13)
Central venous catheter 37 (90%)(plus 1/3 exported cases)
Subclavian vein 24 (59%)
Interval jugular vein 11 (27%)
Axillary 1 (2%)
Unspeciﬁed 2 (5%)
Central venous catheter inserted within 24 h 31 (76%)
Duration (days), median (range) n = 41 5 (1–10)
Faecal collector system (rectal tube) 21 (51%)
Duration (days), median (range) 3 (1–10)
Urinary catheter 27 (53%)
Duration (days), median (range) 2 (1–10)
Intravenous (IV) ﬂuid 40 (98%)
IV Fluid maximum volume (L) in 24 h (median, range) 3.2 (2–8)
IV Fluid median duration (days, range) 5 (2–17)
IV Fluid median duration in survivors (days, range) 5 (2–17)
Intravenous potassium (K+) replacement 31 (76%)
Total K+ (mmol) during admission (median, range) n = 31 200 (20–640)
Intravenous magnesium (Mg2+) replacement 18 (44%)
Total Mg2+ (mmol) during admission (median, range) n = 18 20 (16–156)
Intravenous phosphate (PO43-) replacement 6 (15%)
Total PO43- (mmol) during admission (median, range) n = 6 50 (50–250)
Blood component therapy administered 20 (49%)
Fresh frozen plasma 18 (44%)
Cryoprecipitate 9 (22%)
Platelets 8 (20%)
Packed red blood cells 2 (5%)
Intravenous Ceftriaxone 37 (90%)
Median duration, days (range) 5 (1–10)
Oxygen supplementation 18 (44%)
Median duration, days (range) 3 (1–7)
Table 5 Factors associated with mortality at admission – univariate logistic regression analysis.
Variable Odds ratio 95%CI p-value
Age (year) 0.95 0.89–1.01 0.316
EVD stage >2 8.00 1.93–33.18 0.004
Duration illness pre-admission 0.81 0.64–1.02 0.075
AST >1000 U/L 6.00 1.17–30.72 0.032
RIFLE stage > 2 (injury) 4.80 1.20–19.13 0.002
Granulocyte > 7.5 × 109/L 5.60 1.16–27.08 0.03
Ct value < 20 19.50 3.38–112.05 0.001
NEWS > 5 5.19 1.28–21.08 0.021
AST – aspartate aminotransferase, RIFLE classiﬁcation (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney), Ct – cycle
threshold, NEWS – national early warning score.
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less than 20 (OR 19.5 95% CI 3.38–112.05). EVD stage greater
than 2 (OR 8.0 95% CI 1.93–33.18) and NEWS greater than 5
(OR 5.19 95% CI 1.28–21.08) at admission were associated
with increased mortality.
Discussion
The scale of the EVD outbreak in West Africa presented a
unique opportunity to improve patient outcomes, our under-
standing of the natural history of disease and to evaluate
novel therapeutics. Much has been learnt from both African
cohorts and exported cases in terms of the clinical syndrome
of EVD and the beneﬁts of supportive care provision.19 The
EVDTU at Kerry Town was a small unit dedicated to providing
care for HCWs in a well-resourced clinical environment, with
high quality nursing care and senior clinician leadership,
supported by a comprehensive deployed laboratory. It was
committed to improving equity of access to life saving inter-
ventions and to pushing the boundaries of EVD supportive
care – including central venous catheterisation, ultrasound
guided ﬂuid resuscitation, and laboratory support to guide
electrolyte replacement.
The majority of patients admitted were HCWs and repre-
sent an older and more unwell cohort, compared to other
data sets reported. Nearly half of all patients were also
transferred from other treatment centres and as such pre-
senting later in their disease course. At admission the major-
ity of the cohort had severe EVD, based on a novel EVD
staging system developed by the UK DMS, underpinned by
laboratory and clinical data. Although the total number of
patients admitted with conﬁrmed EVD was smaller than
expected, the unique breadth, depth and completeness of
data collected presents a unique opportunity for detailed
analysis. It is the ﬁrst description of an “EVD care bundle”
based on established tenets of critical care medicine, and
demonstrates the utility of both a novel EVD staging system
and established early warning scores in EVD for the ﬁrst
time.
The majority of the patients had renal impairment with
40% having acute kidney injury by RIFLE criteria, 17/40 with
serum creatinine >350 umol/L, higher than in other pub-
lished cohorts.20,21 Electrolyte imbalance was extremely
common, with hypokalaemia and hypoglycaemia occurring
in the majority of patients, and is to be expected with the
signiﬁcant gastrointestinal involvement in EVD. Potassium
supplementation was required by a number of patients into
the recovery/convalescent phase of illness, and we believe
hypokalaemia induced cardiac arrhythmia may be the cause
of sudden death in recovering patients that was reported by
other clinicians (Dr. M Jalloh – personal communication 2014).
Haemorrhage and signiﬁcant coagulopathy occurred in over
40% of patients, although haemorrhage was not uniformly
fatal with 7/17 (41%, 95% CI 18%–67%) patients surviving to
discharge. This rate is consistent with aggregate data of
exported cases and we believe that it reﬂects higher staff-
to-patient ratios allowing improved case observation, com-
binedwith an interventional approach of placing IV catheters.
Encephalopathy was also frequently seen, and although it
was associated with mortality, 7/26 (27%, 95% CI 12%–48%)
patients with encephalopathy survived. The encephalopathy
that we observed was an alteration in conscious level accom-
panied by transient cognitive impairment, consistent with
diffuse cerebral dysfunction that was hypoactive in nature.
We believe the aetiology is most likely multifactorial, incor-
porating metabolic and infective factors with direct viral
brain involvement possibly contributing.22 Identifying fea-
tures which reliably predict poor clinical outcome at presen-
tation and during the course of illness improve understanding
of disease pathogenesis and can inform future intervention
strategies. In our cohort, factors signiﬁcantly associated with
poor outcome at presentation include a low Ct value, pres-
ence of established organ dysfunction (EVD stage 3) and a
high NEWS score. Other signiﬁcant laboratory variables asso-
ciatedwithmortality in univariate analysis at baseline include
AST, ALT, creatinine, CRP and white blood count. Recent
further analysis of clinical trial data also showed signiﬁcant
electrolyte abnormalities in their EVD cohort and tested a
prognostic model also incorporating calcium and haemoglo-
bin levels.23
Early warning scores aim to identify patients at risk of
severe illness or death, utilising simple physiological param-
eters and have long been advocated by critical care out-
reach and acutemedical teams.18 In keeping with other forms
of critical illness, timely intervention with supportive care
before organ dysfunction becomes established and has the
potential to improve clinical outcomes in EVD. Due to the
limited provision of systematic vital signs monitoring and
data recording in EVD patients in West Africa, limited data
existed to inform development of EVD early warning systems.
We retrospectively analysed our data utilising the UK national
early warning score system and qSOFA scores at baseline,
that in comparison to the novel staging system we report
they do not rely on laboratory parameters. Admission NEWS
score was signiﬁcantly higher in fatal cases, and could be
utilised in the future as a prognostic indictor and planning
tool. The qSOFA showed no utility in predicting outcome in
EVD in our cohort. Although our data set is small it provides
the ﬁrst evidence of the utility of an early warning score in
EVD and requires evaluation in larger cohorts, ideally
prospectively.
The scale and range of medical interventions we report
highlights what is feasible in deployed low-resource set-
tings. Central venous access requires skill, but facilitates
ﬂuid and concentrated electrolyte replacement, limiting inva-
sive procedures.24 Peripherally inserted central lines may
provide an alternative, dependent on operator skill and expe-
rience and were used successfully in 40% of exported cases.14
There were no needlestick injuries associated with central
venous catheters in our staff, and one healthcare worker
infection in an EVDTU nurse, the cause of which was not
identiﬁed. Faecal management systems were also used for
the ﬁrst time in patients with EVD in West Africa. They were
well tolerated by patients and used in 50% of cases, provid-
ing infection prevention and control beneﬁts for staff and
cleanliness and dignity for patients with profuse diarrhoea.
In this cohort of patients with EVD, hypotension refractory
to ﬂuid resuscitation in keeping with the clinical syndrome
of septic shock was not observed and as such vasopressors
were not utilised. We were also fortunate to have access to
comprehensive panel of blood products that were delivered
to almost 50% of patients. The EVDTU was not a clinical trial
site for novel therapeutics during the outbreak and focussed
on delivery of high quality supportive care. However, at
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their own request, and through provision by referring units,
three HCWs received convalescent whole blood transfusion,
providing informed consent and ultimately all surviving their
infection. Subsequent clinical trial data failed to show any
clear beneﬁt of convalescent plasma in EVD.25 Experimental
antiviral therapies had not been used for post-exposure pro-
phylaxis (PEP) in any of cohort, but a number of interna-
tional HCWs did receive (PEP) after high risk exposures and
evacuation to the UK.26
Whilst we rightly emphasise the beneﬁts of comprehen-
sive supportive care for EVD patients we must also recognise
the beneﬁts of palliative care and psychological support in
patients who will not survive. We had established protocols
for end of life care and with higher stafﬁng levels, were able
to provide improved symptom management to fatal cases
with 75% receiving opiate analgesia and 50% benzodiaz-
epines, frequently through syringe drivers. Opiate analgesia
was also utilised in over 50% of survivors, mainly as an oral
formulation.
Healthcare workers at the forefront of the ﬁght against
EVD have suffered consistently high case fatality rates. The
reasons underlying these rates across the outbreak remain
unclear, but older age, comorbidities and high viral load are
consistently associated with poorer outcome and may be
more common in HCWs. A clinical prioritization score devel-
oped by Hartley et al.,27 adjusted for age and viral load
predicted a case fatality rate of 62% in our cohort (95% CI
45%–74%) at admission. The case fatality rate in the military
EVDTU was 49% (95% CI 33%–65%) overall, but direct compar-
ison of clinical outcomes from different treatment facilities
has proved difﬁcult. Rates reported from other ETCs in Sierra
Leone were similar from cohorts with lower median ages and
higher Ct values. International Medical Corps28 reported a
case fatality rate of 58% (95% CI 53%–64%, median Ct 25.4),
and Medicins san Frontieres,29 a case fatality rate of 51%
(95% CI 47%–56%, median Ct 31 in survivors and 22 in fatal
cases). Historical control data for 3 months preceding the
JIKI trial in Guinea had similar Ct values (Adults and chil-
dren ≥6 years Ct value 20.1) with a case fatality rate of 57%
(272/478, 95% CI 52%–61%).30 A study of the heterogeneity in
the case fatality rates inWest Africa,31 was limited bymissing
outcome data, but demonstrated that in the age group 35–39
years there was a case fatality rate of 67.5% (95% CI 62%–
72%, n = 351). Analysis of supplementary data from this
study also showed that in adults (≥17 years, median age 32
years) with conﬁrmed EVD and known outcome status admit-
ted to ETCs in Sierra Leone, there were 268/477 deaths (CFR
56%, 95% CI 52–61). Whilst the difﬁculty of comparing out-
comes in cohorts with signiﬁcantly different demographics
and baseline viral loads is obvious, the importance of survi-
vor bias due to local factors affecting patient distribution
must also be considered.32
A number of limitations of our data must be appreciated,
that reﬂect the primary mission of the EVDTU to manage
infected HCWs. As such paediatric or pregnant cases were
not referred to the EVDTU, that may have different clinical
syndromes and management approaches. The EVDTU was
also highly resourced with its main assets being staff-to-
patient ratios and laboratory support. The intensive medical
and nursing care provided would be challenging to safely
maintain in larger ETCs, but a compromise incorporating the
tenets of ourmanagement approach is achievable. The number
of HCWcases thatwere admittedwas also lower than expected
resulting in a small sample size. This reﬂects the timing of
the epidemic and reduced nosocomial risk to HCWs as better
treatment centres opened, and is consistent with the expe-
rience of other HCW ETCs in Guinea and Liberia. Small sample
size has prevented us from performing multivariable analysis
to looking at the risk factors of mortality at admission simul-
taneously. As a result, observed differences may be subject
to possible confounding effects due to unknown or unmea-
sured factors.
In resource-limited African settings, the provision of even
basic supportive care to patients with EVD is difﬁcult. Rec-
ommendations to limit treatment based upon perceived poor
patient prognosis and risk to HCWs, perpetuate the cycle of
limited care, poor outcomes and fear.33 Whilst the provision
of renal replacement therapy and mechanical ventilation
have been successfully utilised in one ETC in Sierra Leone
during the recent outbreak, the logistic and practical con-
siderations of providing level 3 care, unfortunately makes it
an unrealistic proposition as an established level of care for
EVD in future outbreaks.We do recognise that when resources
and appropriately trained personnel exist, this capability
can be safely delivered and will improve outcomes in severe
EVD for limited numbers of patients. We believe that the
approach pioneered at our EVDTUutilising improved resources,
clinical staging of disease severity and an enhanced level of
protocolized care offers a blueprint for the future manage-
ment of EVD in resource-limited environments. These pro-
cesseswere subsequently adopted by other non-governmental
organisations in West Africa, and can form a platform for
future viral haemorrhagic fever clinical care augmented by
speciﬁc therapeutics when available.
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